Patient-centered Approaches to Reduce Treatment Burden and Optimize Anatomical and Visual Outcomes in nAMD and DME

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the American Macular Degeneration Foundation (AMDF)

ACKNOWLEDGEMENT

Supported by an educational grant from Genentech, a member of the Roche Group.

DATE OF RELEASE/EXPIRATION

This activity was released on February 28, 2024 and is valid until February 28, 2025. Requests for credit must be made no later than February 28, 2025.

TARGET AUDIENCE

The primary target audience for this activity includes Ophthalmology and retina specialist clinicians (MDs/DOs/NPs/PAs), optometrists, primary care clinicians, and diabetes educators.

STATEMENT OF NEED/PROGRAM OVERVIEW

Anti-VEGF agents initially approved for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are limited by the need for frequent intravitreal injections and the potential for adverse events. New anti-angiogenesis agents and novel intravitreal delivery systems have the potential to reduce treatment burden and improve quality of life based on their proven efficacy and rapid and sustained impacts on anatomical and visual outcomes.

Join an expert panel of ophthalmologists and a patient/caregiver to discuss the efficacy and safety of new treatment options that can help ophthalmologists and other clinicians to deliver optimal patient-centered care. The panel will also define the place of new and emerging treatment options in nAMD and DME, with the goal of providing rapid and vision-sustaining benefits.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe patient- and non-patient-related barriers that prevent people with nAMD or DME from obtaining full benefit from anti-VEGF therapies.
• Summarize evidence from clinical trials with newer agents on durable vision gains and retinal fluid reduction in nAMD and DME.
• Review clinical trials and real-world evidence on individualized injection frequency and rapid efficacy with newer nAMD and DME treatments.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 45 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.